Transcode Therapeutics EV/EBIT
The EV/EBIT (Enterprise Value to EBIT) of Transcode Therapeutics (RNAZ) as of Oct 20, 2026 is -0.31. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -0.51 — a change of -40.21% (higher).
Get this data via API
Financial Data API
EV/EBIT
-0.31
YoY
-40.21%
Last updated:
The Transcode Therapeutics EV/EBIT history
3 Years
10 Years
25 Years
Max
| YEAR | EV/EBIT | YoY |
|---|---|---|
| est | -0.09 | -70.50% |
| -0.31 | -40.21% | |
| -0.51 | +16.08% | |
| -0.44 | -3.88% | |
| -0.46 | -63.85% | |
| -1.27 | -89.23% | |
| -11.75 | -37.12% | |
| -18.69 | -15.95% | |
| -22.23 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Transcode Therapeutics Stock analysis
Frequently Asked Questions about Transcode Therapeutics stock
EV/EBIT (Enterprise Value to EBIT) of Transcode Therapeutics is -0.31 in 2025.
EV/EBIT (Enterprise Value to EBIT) of Transcode Therapeutics changed from -0.51 to -0.31, representing a -40.21% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Transcode Therapeutics since 2006 – with annual values, charts, and detailed analysis.
The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.
EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes
To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).
A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Transcode Therapeutics with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Valuation — Transcode Therapeutics
All Key Metrics — Transcode Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth